Buckstein R. Updates on the management of myelodysplastic syndromes and incorporation of novel agents. Education Session. ASCO 2021. Abstract
DiNardo C et al. A randomized, double-blind, placebo-controlled study of venetoclax with azacitidine vs azacitidine in treatment-naïve patients with acute myeloid leukemia ineligible for intensive therapy-viale-a. EHA 2020;Abstract LB2601.
DiNardo CD et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med 2020;383(7):617-29. Abstract
Fenaux P et al. Luspatercept in patients with lower-risk myelodysplastic syndromes. N Engl J Med 2020;382(2):140-51. Abstract
Garcia JS et al. Molecular responses are observed across mutational spectrum in treatment-naïve higher-risk myelodysplastic syndrome patients treated with venetoclax plus azacitidine. ASH 2021;Abstract 241.
Garcia-Manero G et al. Oral decitabine/cedazuridine in patients with lower risk myelodysplastic syndrome: A longer-term follow-up from the ASCERTAIN study. ASH 2021;Abstract 66.
Jonas BA, Pollyea DA. How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia. Leukemia 2019;33(12):2795-804. Abstract
Montesinos P et al. Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia. N Engl J Med 2022;386(16):1519-31. Abstract
Pratz KW et al. Cytopenia management in patients with newly diagnosed acute myeloid leukemia treated with venetoclax plus azacitidine in the VIALE-A study. ASH 2020;Abstract 1944.
Pratz KW et al. Measurable residual disease response and prognosis in treatment-naïve acute myeloid leukemia with venetoclax and azacitidine. J Clin Oncol 2022;40(8):855-65. Abstract
Wei AH et al. A phase 3 study of venetoclax plus low-dose cytarabine in previously untreated older patients with acute myeloid leukemia (VIALE-C): A 6-month update. EHA 2020;Abstract S136.
Wei AH et al. 6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy (141/150). Blood Cancer J 2021;11(10):163. Abstract
Wei AH et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: A phase 3 randomized placebo-controlled trial Blood 2020;135(24):2137-45. Abstract
Zeidan AM et al. Phase 3 VERONA study of venetoclax with azacitidine to assess change in complete remission and overall survival in treatment-naïve higher-risk myelodysplastic syndromes. ASCO 2021;Abstract TPS7054.